LifeVantage Corporation filings document formal disclosures for a Nasdaq-listed health and wellness company that sells nutrigenomic supplements, skin and hair care products, energy drink mixes, and pet supplements through an independent Consultant model. Recent Form 8-K reports furnish quarterly operating results and describe revenue by region, earnings measures, capital allocation, and material corporate events.
Proxy and meeting filings cover board elections, advisory executive compensation votes, auditor ratification, incentive-plan matters, and final stockholder voting results. Other current reports address executive departures, officer appointments, board changes, transition agreements, and compensatory arrangements, alongside exhibit-based press releases tied to financial results and governance actions.
Lifevantage Corp (LFVN) Chief Sales Officer Kristen Cunningham acquired 32,850 stock units, each a right to one common share, and 49,275 performance restricted stock units on October 7, 2026. Her reported direct common-stock holdings after the stock-unit award were 152,375 shares. The stock units vest in three equal installments on October 7, 2027, October 7, 2028 and October 7, 2029, subject to continued service. The PRSUs vest only to the extent financial performance targets are achieved over a three-and-a-half-year period from October 2026 through March 2030 and subject to continued service; at maximum performance, Cunningham may become eligible to earn 150% of the target number of units.
Lifevantage Corp (LFVN) Chief Financial Officer Carl Aure reported awards on October 7, 2026, covering 35,749 stock units and 53,623 performance restricted stock units (PRSUs), each representing a right to receive common stock. The stock units vest in thirds subject to continued service; the PRSUs vest only to the extent financial performance targets are achieved over a three-and-a-half-year period ending in March 2030, subject to continued service. At maximum performance, Aure may become eligible to earn 150% of the PRSU target. The common-stock row reports 191,784 shares following the transaction.
Lifevantage Corp (LFVN) reported grant awards to President and CEO Terrence Moorehead on October 7, 2026: a 193,237-unit stock award and 289,855 performance restricted stock units (PRSUs). The transaction rows report 501,879 directly held common shares following the stock award and 289,855 PRSUs following the PRSU award.
Each stock unit represents a right to receive one common share and vests in thirds on October 7, 2027, October 7, 2028, and October 7, 2029, subject to continued service. PRSUs vest only to the extent performance targets are achieved and continued-service conditions are met; at maximum performance, Moorehead may become eligible to earn 150% of the target units.
Lifevantage Corp (LFVN) Chief Financial Officer Carl Aure reported that 460 shares of common stock were delivered or withheld on October 1, 2026, for payment of exercise price or tax liability. The reported price was $6.24 per share. Aure held 156,035 shares directly after the transaction.
Lifevantage Corp (LFVN) Chief Sales Officer Kristen Cunningham reported 637 shares of common stock delivered or withheld for payment of exercise price or tax liability on October 1, 2026. The reported price was $6.24 per share. The transaction was classified as a direct disposition, and Cunningham directly held 119,525 shares of common stock following the transaction.
Lifevantage Corporation (LFVN)’s Board approved a change in the company’s fiscal year end from June 30 to December 31 on September 29, 2026, aligning it with the calendar year. The change creates a transition period from July 1, 2026, to December 31, 2026. The company expects to file a Form 10-KT with audited financial statements for that period.
LifeVantage Corporation (LFVN) is asking stockholders to vote at its fiscal 2027 Annual Meeting, to be held in person on November 5, 2026 at 1:00 p.m. MT in Lehi, Utah, on three main items: electing six directors, approving a non‑binding Say‑On‑Pay vote on executive compensation, and ratifying Deloitte & Touche LLP as independent auditor for the year ending June 30, 2027.
The record date is September 14, 2026, when 12,589,444 common shares were outstanding. The board, led by independent chair Raymond Greer, highlights recent governance and strategy changes, including leadership transition to new CEO Terrence Moorehead, board refreshment, majority voting for directors, high director stock‑ownership guidelines, and expanded stockholder engagement. 2026 pay for former CEO Steven Fife totaled $2.19 million, while Chief Sales Officer Kristen Cunningham and CFO Carl Aure earned $815,439 and $756,663, respectively, with a mix of base salary, annual incentives at 10% of target, and performance‑based equity.
Lifevantage Corp (LFVN) reports that director Lewis Darwin purchased common stock in the company. On September 15, 2026, he bought 976 shares at $6.22 per share in an open-market or private transaction, increasing his directly held stake to 138,244 shares. The filing affirms that this trade was made under a Rule 10b5-1 trading plan.
Lifevantage Corp (LFVN) reported that its Chief Financial Officer, Carl Aure, had 1,869 shares of common stock withheld or delivered on September 10, 2026 to pay the exercise price or related tax liability at a reported price of $6.37 per share. After this transaction, he held 156,495 shares directly, which include 2,810 shares purchased on August 31, 2026 under the Employee Stock Purchase Plan. No Rule 10b5-1 trading plan is reported for this transaction.